Please enable JavaScript to continue using this application.

Compare $BEAM vs $SLS | Chartloom

Compare

$BEAM vs $SLS

Beam Therapeutics Inc · Sellas Life Sciences Group Inc

BEAM

Beam Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Compare $BEAM vs $SLS

Comparing Beam Therapeutics Inc and Sellas Life Sciences Group Inc

BEAMBeam Therapeutics Inc

SLSSellas Life Sciences Group Inc

BEAMBeam Therapeutics Inc

Market cap

$2.64B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

38.86x

Rev growth (TTM)

158.9%

YTD performance

-5.3%

52W performance

-4.8%

FCF yield

-14.1%

SLSSellas Life Sciences Group Inc

Market cap

$2.29B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

167.8%

52W performance

503.6%

FCF yield

-1.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BEAM

SLS

Detailed metrics comparison

BEAM

Beam Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Market Cap

BEAM$2.64B

SLS$2.29B

Enterprise Value

BEAM$2.52B

SLS$2.15B

Price

BEAM$25.70

SLS$11.65

P/E Ratio

BEAMN/A

SLSN/A

P/S Ratio

BEAM16.95x

SLS817.53x

EV/Sales

BEAM16.18x

SLS769.83x

EV/EBITDA

BEAM0.00x

SLS0.00x

P/B Ratio

BEAM2.37x

SLS17.22x

P/FCF Ratio

BEAMN/A

SLSN/A

EV/FCF

BEAM-6.77x

SLS-75.73x

PEG Ratio

BEAMN/A

SLSN/A

Forward P/E (NTM)

BEAMN/A

SLSN/A

Forward P/S (NTM)

BEAM38.86x

SLSN/A

Revenue (TTM)

BEAM$156M

SLS$0

Revenue Growth (YoY)

BEAM158.9%

SLSN/A

Forward Rev Growth

BEAM17.9%

SLS144.9%

Gross Margin (TTM)

BEAM0.0%

SLS93.1%

Operating Margin (TTM)

BEAM0.0%

SLS0.0%

EBITDA Margin (TTM)

BEAM-228.0%

SLS0.0%

Net Margin (TTM)

BEAM-54.7%

SLS0.0%

FCF Margin (TTM)

BEAM-238.9%

SLSN/A

Net Income (TTM)

BEAM$-85M

SLS$-32M

FCF (TTM)

BEAM$-373M

SLS$-28M

EPS (TTM)

BEAM-$0.82

SLS-$0.17

ROE (TTM)

BEAM-770.0%

SLS-3591.0%

ROA (TTM)

BEAM-604.0%

SLS-3334.0%

ROIC (TTM)

BEAM-737.0%

SLS-3591.0%

Cash

BEAM$220M

SLS$138M

Debt

BEAM$100M

SLS$0

Net Cash/Debt

BEAM$120M

SLS$138M

Current Ratio (TTM)

BEAM14.57x

SLS18.83x

Quick Ratio (TTM)

BEAM14.25x

SLS18.29x

Debt/Equity (TTM)

BEAM0.09x

SLS0.00x

Debt/Assets (TTM)

BEAM0.0%

SLS0.0%

Interest Coverage (TTM)

BEAMN/A

SLSN/A

Net Debt/EBITDA (TTM)

BEAM0.00x

SLS0.00x

Beta

BEAM2.26

SLS2.68

52W Performance

BEAM-4.8%

SLS503.6%

YTD Performance

BEAM-5.3%

SLS167.8%

% from 52W High

BEAM-32.8%

SLS-26.6%

% from 52W Low

BEAM27.0%

SLS738.1%

Asset Turnover (TTM)

BEAM0.11x

SLS0.09x

FCF Yield (TTM)

BEAM-14.1%

SLS-1.2%

Earnings Yield (TTM)

BEAM-3.2%

SLS-1.4%

Dividend Yield (TTM)

BEAMN/A

SLSN/A

Rule of 40

BEAM-80.0

SLS0.0

EV/GP/RG

BEAMN/A

SLSN/A

Ticker research

View BEAM research View SLS research

Metric	BEAM Beam Therapeutics Inc	SLS Sellas Life Sciences Group Inc
Market & Valuation
Market Cap	$2.64B	$2.29B
Enterprise Value	$2.52B	$2.15B
Price	$25.70	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	16.95x	817.53x
EV/Sales	16.18x	769.83x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.37x	17.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.77x	-75.73x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	38.86x	N/A
Revenue & Growth
Revenue (TTM)	$156M	$0
Revenue Growth (YoY)	158.9%	N/A
Forward Rev Growth	17.9%	144.9%
Profitability
Gross Margin (TTM)	0.0%	93.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-228.0%	0.0%
Net Margin (TTM)	-54.7%	0.0%
FCF Margin (TTM)	-238.9%	N/A
Net Income (TTM)	$-85M	$-32M
FCF (TTM)	$-373M	$-28M
EPS (TTM)	-$0.82	-$0.17
ROE (TTM)	-770.0%	-3591.0%
ROA (TTM)	-604.0%	-3334.0%
ROIC (TTM)	-737.0%	-3591.0%
Financial Health
Cash	$220M	$138M
Debt	$100M	$0
Net Cash/Debt	$120M	$138M
Current Ratio (TTM)	14.57x	18.83x
Quick Ratio (TTM)	14.25x	18.29x
Debt/Equity (TTM)	0.09x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.26	2.68
52W Performance	-4.8%	503.6%
YTD Performance	-5.3%	167.8%
% from 52W High	-32.8%	-26.6%
% from 52W Low	27.0%	738.1%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.09x
FCF Yield (TTM)	-14.1%	-1.2%
Earnings Yield (TTM)	-3.2%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-80.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BEAM research	View SLS research

Valuation

P/S Ratio

BEAM

16.95x

SLS

817.53x

EV/FCF

SLS

-75.73x

BEAM

-6.77x

Growth & revenue

Revenue Growth TTM

BEAM

158.9%

Forward Revenue Growth

SLS

144.9%

BEAM

17.9%

Profitability & performance

Gross Margin

SLS

93.1%

BEAM

0.0%

ROE

BEAM

-770.0%

SLS

-3591.0%

FCF Yield %

SLS

-1.2%

BEAM

-14.1%

52-Week Performance

SLS

503.6%

BEAM

-4.8%

Detailed metrics comparison

BEAM

Beam Therapeutics Inc

SLS

Sellas Life Sciences Group Inc

Market Cap

BEAM$2.64B

SLS$2.29B

Enterprise Value

BEAM$2.52B

SLS$2.15B

Price

BEAM$25.70

SLS$11.65

P/E Ratio

BEAMN/A

SLSN/A

P/S Ratio

BEAM16.95x

SLS817.53x

EV/Sales

BEAM16.18x

SLS769.83x

EV/EBITDA

BEAM0.00x

SLS0.00x

P/B Ratio

BEAM2.37x

SLS17.22x

P/FCF Ratio

BEAMN/A

SLSN/A

EV/FCF

BEAM-6.77x

SLS-75.73x

PEG Ratio

BEAMN/A

SLSN/A

Forward P/E (NTM)

BEAMN/A

SLSN/A

Forward P/S (NTM)

BEAM38.86x

SLSN/A

Revenue (TTM)

BEAM$156M

SLS$0

Revenue Growth (YoY)

BEAM158.9%

SLSN/A

Forward Rev Growth

BEAM17.9%

SLS144.9%

Gross Margin (TTM)

BEAM0.0%

SLS93.1%

Operating Margin (TTM)

BEAM0.0%

SLS0.0%

EBITDA Margin (TTM)

BEAM-228.0%

SLS0.0%

Net Margin (TTM)

BEAM-54.7%

SLS0.0%

FCF Margin (TTM)

BEAM-238.9%

SLSN/A

Net Income (TTM)

BEAM$-85M

SLS$-32M

FCF (TTM)

BEAM$-373M

SLS$-28M

EPS (TTM)

BEAM-$0.82

SLS-$0.17

ROE (TTM)

BEAM-770.0%

SLS-3591.0%

ROA (TTM)

BEAM-604.0%

SLS-3334.0%

ROIC (TTM)

BEAM-737.0%

SLS-3591.0%

Cash

BEAM$220M

SLS$138M

Debt

BEAM$100M

SLS$0

Net Cash/Debt

BEAM$120M

SLS$138M

Current Ratio (TTM)

BEAM14.57x

SLS18.83x

Quick Ratio (TTM)

BEAM14.25x

SLS18.29x

Debt/Equity (TTM)

BEAM0.09x

SLS0.00x

Debt/Assets (TTM)

BEAM0.0%

SLS0.0%

Interest Coverage (TTM)

BEAMN/A

SLSN/A

Net Debt/EBITDA (TTM)

BEAM0.00x

SLS0.00x

Beta

BEAM2.26

SLS2.68

52W Performance

BEAM-4.8%

SLS503.6%

YTD Performance

BEAM-5.3%

SLS167.8%

% from 52W High

BEAM-32.8%

SLS-26.6%

% from 52W Low

BEAM27.0%

SLS738.1%

Asset Turnover (TTM)

BEAM0.11x

SLS0.09x

FCF Yield (TTM)

BEAM-14.1%

SLS-1.2%

Earnings Yield (TTM)

BEAM-3.2%

SLS-1.4%

Dividend Yield (TTM)

BEAMN/A

SLSN/A

Rule of 40

BEAM-80.0

SLS0.0

EV/GP/RG

BEAMN/A

SLSN/A

Ticker research

View BEAM research View SLS research

Metric	BEAM Beam Therapeutics Inc	SLS Sellas Life Sciences Group Inc
Market & Valuation
Market Cap	$2.64B	$2.29B
Enterprise Value	$2.52B	$2.15B
Price	$25.70	$11.65
P/E Ratio	N/A	N/A
P/S Ratio	16.95x	817.53x
EV/Sales	16.18x	769.83x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.37x	17.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.77x	-75.73x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	38.86x	N/A
Revenue & Growth
Revenue (TTM)	$156M	$0
Revenue Growth (YoY)	158.9%	N/A
Forward Rev Growth	17.9%	144.9%
Profitability
Gross Margin (TTM)	0.0%	93.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-228.0%	0.0%
Net Margin (TTM)	-54.7%	0.0%
FCF Margin (TTM)	-238.9%	N/A
Net Income (TTM)	$-85M	$-32M
FCF (TTM)	$-373M	$-28M
EPS (TTM)	-$0.82	-$0.17
ROE (TTM)	-770.0%	-3591.0%
ROA (TTM)	-604.0%	-3334.0%
ROIC (TTM)	-737.0%	-3591.0%
Financial Health
Cash	$220M	$138M
Debt	$100M	$0
Net Cash/Debt	$120M	$138M
Current Ratio (TTM)	14.57x	18.83x
Quick Ratio (TTM)	14.25x	18.29x
Debt/Equity (TTM)	0.09x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.26	2.68
52W Performance	-4.8%	503.6%
YTD Performance	-5.3%	167.8%
% from 52W High	-32.8%	-26.6%
% from 52W Low	27.0%	738.1%
Efficiency & Yields
Asset Turnover (TTM)	0.11x	0.09x
FCF Yield (TTM)	-14.1%	-1.2%
Earnings Yield (TTM)	-3.2%	-1.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-80.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BEAM research	View SLS research